These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1028 related items for PubMed ID: 16479544

  • 1. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [Abstract] [Full Text] [Related]

  • 2. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E.
    Cancer Res; 2008 Feb 01; 68(3):901-8. PubMed ID: 18245493
    [Abstract] [Full Text] [Related]

  • 3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct 01; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

  • 4. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB.
    J Immunol; 1997 Apr 01; 158(7):3325-34. PubMed ID: 9120290
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP.
    Cancer Res; 2001 Aug 15; 61(16):6219-26. PubMed ID: 11507075
    [Abstract] [Full Text] [Related]

  • 6. Dominant expression of interleukin-10 and transforming growth factor-beta genes in activated T-cells of chronic active Epstein-Barr virus infection.
    Ohga S, Nomura A, Takada H, Tanaka T, Furuno K, Takahata Y, Kinukawa N, Fukushima N, Imai S, Hara T.
    J Med Virol; 2004 Nov 15; 74(3):449-58. PubMed ID: 15368517
    [Abstract] [Full Text] [Related]

  • 7. High frequency of EBV association and 30-bp deletion in the LMP-1 gene in CD56 lymphomas of the upper aerodigestive tract.
    Tai YC, Kim LH, Peh SC.
    Pathol Int; 2004 Mar 15; 54(3):158-66. PubMed ID: 14989738
    [Abstract] [Full Text] [Related]

  • 8. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y, Kondo E, Demachi-Okamura A, Akatsuka Y, Tsujimura K, Tanimoto M, Morishima Y, Takahashi T, Kuzushima K.
    J Virol; 2006 Jan 15; 80(2):883-90. PubMed ID: 16378990
    [Abstract] [Full Text] [Related]

  • 9. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.
    Diekmann J, Adamopoulou E, Beck O, Rauser G, Lurati S, Tenzer S, Einsele H, Rammensee HG, Schild H, Topp MS.
    J Immunol; 2009 Aug 01; 183(3):1587-97. PubMed ID: 19587004
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
    Ren Q, Sato H, Murono S, Furukawa M, Yoshizaki T.
    Laryngoscope; 2004 May 01; 114(5):855-9. PubMed ID: 15126743
    [Abstract] [Full Text] [Related]

  • 11. Correlation of immunophenotype of sinonasal non-Hodgkin's lymphoma to Epstein-Barr virus infection.
    Feng YF, Wu QL, Zong YS.
    Ai Zheng; 2007 Nov 01; 26(11):1170-6. PubMed ID: 17991313
    [Abstract] [Full Text] [Related]

  • 12. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.
    Blood; 2003 Mar 01; 101(5):1905-12. PubMed ID: 12411306
    [Abstract] [Full Text] [Related]

  • 13. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
    Chiang AK, Tao Q, Srivastava G, Ho FC.
    Int J Cancer; 1996 Nov 04; 68(3):285-90. PubMed ID: 8903467
    [Abstract] [Full Text] [Related]

  • 14. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG.
    Cancer Surv; 1992 Nov 04; 13():53-80. PubMed ID: 1330300
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T-cell antigens by tumour cells.
    Kanavaros P, Briere J, Lescs MC, Gaulard P.
    J Pathol; 1996 Mar 04; 178(3):297-302. PubMed ID: 8778335
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R.
    Blood; 2003 Apr 15; 101(8):3150-6. PubMed ID: 12468425
    [Abstract] [Full Text] [Related]

  • 17. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y.
    Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466
    [Abstract] [Full Text] [Related]

  • 18. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
    Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM.
    J Infect Dis; 1999 May 20; 179(5):1108-15. PubMed ID: 10191211
    [Abstract] [Full Text] [Related]

  • 19. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ, Sili U, Gahn B, Vigouroux S, Huls MH, Xie W, Vignali D, Brenner MK, Heslop HE, Rooney CM.
    Cytotherapy; 2003 May 20; 5(3):231-40. PubMed ID: 12850791
    [Abstract] [Full Text] [Related]

  • 20. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, Johnson PJ.
    J Med Virol; 2002 Jul 20; 67(3):359-63. PubMed ID: 12116028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.